TrialJournal of gastroenterology2013

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.

Stefan Boeck et al.PubMed ↗Publisher ↗

No numbers read from the abstract.